Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (14912)	2/12/1998 6:21:00 PM
From: Henry Niman	Respond to of 32384

Bob, There's clinical data on Targretin (and all of LGND's compounds in trials) at home.att.net Targretin is in Phase II/III trials for CTCL. The Phase I/II data showed that it was effective against new and advanced cases. Virtually all patients responded from stabilization of disease to complete remission, even in refractory cases. Targretin has also been used to treat advanced lung cancer. In those instances there was stabilization of disease (but not tumor reduction). In general, the longer the patients are on the medications (Targretin and Panretin), the greater the improvement. I believe that Phase II data on Targretin treatment of ovarian cancer is due out soon.